Skip to Content

Global Oncology Leaders to Convene in Dublin for NCODA 2027 Congress on the Future of Cancer Care

Published Date:

International experts to explore emerging treatments, healthcare innovation and the challenges of delivering patient-centred cancer care.

Dublin, Ireland, 19th November 2026 — Following the resounding success of its inaugural meeting, the Network for Collaborative Oncology Development & Advancement (NCODA) today officially announces that its Global Oncology & Haematology Congress will return to Dublin in March 2027, with Croke Park confirmed as the venue.

Building on the momentum of international collaboration established in March 2026, the 2027 Congress will bring together global leaders, clinicians and experts across the oncology ecosystem to explore the clinical advances and practical challenges shaping the future of cancer care.

With oncology evolving at an unprecedented pace, the Congress will provide an important opportunity to connect emerging science with the realities of clinical practice and the delivery of patient-centred care. Across 16 sessions, internationally recognised faculty will examine developments in treatment and technology, the changing needs of patients and healthcare professionals, and the importance of collaboration in translating innovation into meaningful improvements in cancer care.

Through five key areas of focus, the 2027 programme will examine what it takes to advance cancer care, from the latest clinical breakthroughs to the practical realities of delivering them:

  • Clinical Advances and Emerging Therapies: Examining developments in breast and gastrointestinal cancer care, precision oncology, cellular therapies and new treatment modalities, alongside insights into the global clinical trial landscape and therapies with the potential to change clinical practice.
  • Quality, Safety and Integrated Care: Exploring strategies to address drug supply disruptions and falsified medicines, as well as the role of medically integrated dispensing and international accreditation in strengthening standards and supporting safe, coordinated cancer care.
  • Technology and a Sustainable Oncology Workforce: Considering how emerging technologies can transform oncology practice and strengthen workforce capacity, alongside approaches to supporting mental health, resilience and addressing professional burnout.
  • Patient Experience and Access: Highlighting opportunities to advance patient navigation and survivorship, improve care in resource-constrained settings, and strengthen collaboration across the oncology ecosystem to ensure innovation reaches the patients who need it.
  • Leadership, Policy and Advocacy: Exploring practical approaches to driving lasting change and advancing policies that support the delivery of high-quality cancer care.

Michael Reff, RPh, MBA, Founder and Executive Director of NCODA, expressed the significance of the 2027 return:

“Our inaugural Congress in Dublin demonstrated the real value of bringing together international expertise and perspectives to address the challenges facing oncology care. As the pace of clinical innovation continues to accelerate, it is equally important that we consider how these advances can be translated into meaningful improvements for patients. The 2027 Congress will create a space for global leaders to share knowledge, challenge thinking and explore practical solutions across the many dimensions of cancer care, from emerging therapies and technology to workforce sustainability and patient access.”

Dave Shanahan, NCODA Global Congress Steering Committee Member and CEO of Athena Pharmaceuticals, noted the strategic importance of the Dublin location:

“Dublin is once again an important meeting point for the international oncology community. The breadth of the 2027 programme reflects the complexity of cancer care today and the need to look beyond individual treatments or technologies to consider the wider ecosystem in which care is delivered. By bringing together clinicians, researchers, industry leaders and other key stakeholders, the Congress provides an opportunity to share international experience, encourage collaboration and explore how we can turn innovation into better, more accessible and more patient-centred care.”

Registration is now open for the 2027 Congress. Delegates who register by 29th January, 2027 can avail of reduced early registration rates of €110 for practising professionals and €65 for students and trainees. Standard registration rates of €220 and €130, respectively, will apply after this date.

Further information on the Global Oncology & Haematology Congress is available at https://ncoda.org/events/2027-ncoda-global-oncology-amp-haematology-congress/.

 

For interviews or media enquiries, please contact: 

Ciara O’Driscoll | Etch Communications | [email protected]  | 087 689 3600

About NCODA
The Network for Collaborative Oncology Development & Advancement (NCODA) is a globally recognised non-profit organisation dedicated to improving quality, safety, and access in oncology care. Through standards development, education, and collaboration, NCODA supports healthcare teams worldwide in delivering patient-centred, medically integrated oncology care. See www.ncoda.org for more information.